Abstract: SA-OR55
Association Between Circulating Extracellular Matrix (ECM)-Associated Molecules and Cardiovascular Outcomes in Hemodialysis Patients
Session Information
- Hemodialysis Care: Cardiovascular and Patient-Reported Outcomes
November 04, 2023 | Location: Room 120, Pennsylvania Convention Center
Abstract Time: 05:33 PM - 05:42 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Baek, Jihyun, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea (the Republic of)
- Lee, Yu ho, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea (the Republic of)
- Lee, So-young, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea (the Republic of)
- Jeong, Hyeyun, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea (the Republic of)
- Kim, Jin sug, Kyung Hee University, Seoul, Korea (the Republic of)
- Hwang, Hyeon Seok, Kyung Hee University, Seoul, Korea (the Republic of)
Background
The extracellular matrix (ECM) is a complex network of non-cellular components that provide structural support for the tissues. Circulating ECM-associated molecules are increased during cardiovascular (CV) remodeling process and can be potential biomarkers of adverse CV outcomes. However, their clinical significance in hemodialysis patients is unclear.
Methods
A total of 372 hemodialysis patients were enrolled from a prospective multicenter cohort study. We measured four plasma ECM-associated proteins: matrix metalloproteinase (MMP)-2, MMP-9, tenascin-C, and thrombospondin-2. The primary outcome was set as a composite of cardiac and noncardiac vascular events.
Results
Plasma MMP-2 levels were significantly higher in patients with future CV events than in those without (p = 0.004), while the others were not. All the measured molecules had significant correlations with NT-proBNP levels, but the correlation coefficient was most strong with plasma MMP-2 (Rho = 0.317, p < 0.001). In logistic regression analysis, elevated plasma MMP-2 levels were independently associated with LV diastolic dysfunction (adjusted odds ratio [OR] per standard deviation, 1.48; 95% confidence interval [CI], 1.05 – 2.08; p = 0.024). Cox regression analysis showed that plasma MMP-2 levels were associated with a 1.30-fold risk for the composite of CV events (per a standard deviation increase; 95% CI, 1.04 – 1.63; p = 0.022) after multivariable adjustments
Conclusion
Plasma MMP-2 levels were independently associated with an increased risk of LV diastolic dysfunction and adverse CV outcomes in hemodialysis patients. Our results suggest that MMP-2 levels can be a useful biomarker in identifying hemodialysis patients at high risk of future CV events.